

Debiopharm Investment strengthens its presence in the renewable energy sector

Lausanne, Switzerland –January 23, 2017– Debiopharm Investment SA announces an investment in a company created by Ardian Infrastructure to build and operate a 76MW wind farm in Southern Sweden - one of the best areas for onshore wind in Europe.

The site, whose commissioning is anticipated in the last quarter of 2017, will be equipped with twenty-two V126 3.45 MW Vestas turbines with a target full-year production of 234 GWh. The Swedish developer Rabbalshede Kraft will supervise the construction and will be responsible for all technical and commercial activities of the wind farm once operational.

Google has entered into a long-term Power Purchase Agreement for the entire production of the wind farm. This agreement is in line with Google's goal of sourcing 100% of its power usage from renewable sources. Electricity certificates will also be sold forward.

Through this operation, Debiopharm Investment SA reinforces its presence in the renewable energy sector, with more than 140 MW of installed capacity (wind and solar) financed to date.

About Debiopharm Investment

Debiopharm Investment SA pursues its mission to preserve, diversify and support the sustainable growth of Debiopharm Group™, a biopharmaceutical development company based in Lausanne (Switzerland), through a comprehensive investment strategy centered on three areas of activity: Finance (portfolio management, currency hedging), Real Estate (residential and commercial) and Private Equity.

The Private Equity team focuses primarily on investment diversification, managing a portfolio of funds and of direct equity investments, as minority shareholder, in the capital of pioneering start-ups as well as small and medium-sized European companies.

Our entrepreneurial culture, as well as our willingness and capacity to act as long-term partners of the teams with which we invest, are the established pillars of our commitment.

For more information, please visit www.debiopharm.com

Legal advisor

Gide Loyrette Nouel : Hugues Scalbert, Alexis Pailleret

Debiopharm Investment SA Contact

M. Sébastien Potet
Private Equity Manager
private-equity@debiopharm.com
Tél.: +41 (0) 21 321 01 11